TrialAnnals of surgical oncology2024

Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.

Thorsten O Goetze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.